Physicians are inherently storytellers - witnessing life’s most intimate moments of joy and sorrow through the lens of our patients. Honored to share a remarkable patient story which had a profound impact on me, published in the JCO. The Will to Go On: ascopubs.org/doi/full/10.12…

Enjoyed the discussion here with Dr. Schapira (Lidia Schapira) - ever insightful and the best podcast voice in the business :) Hope to encourage more physicians to reflect, write, and share these special moments we're privileged to witness everyday. #MedTwitter Stanford Cancer Institute

September is #ProstateCancer Awareness Month. Stanford #CME has created a number of resources for both the specialist & #primarycare provider. Check out our podcast episodes, webinars & online learning module. Stanford Department of Medicine Learn more: prostatecancer.stanford.edu

Thank you for the opportunity to tell the story of a beautiful couple. We learn so much through our patients. 🙏🏽

IL-15 in BCG-unresponsive NMIBC NEJM CRs were achieved with a persistence of effect, cystectomy avoidance, and 100% bladder cancer–specific survival at 24 months #bladdercancer Impressive results Amer. Urol. Assn. EAU Edu Platform UROONCO European Urology European Urology Oncology Eurasian Uro-oncological Association Peter Black

Now Available: #ProstateCancer #CME Series: Clinical Case Scenarios for Specialists Test your knowledge & skills by examining 2 prostate cancer patients in this on-demand, interactive program. #MedEd Click here to begin: bit.ly/3hx76hk

Congrats to all our Stanford Medicine students who matched today. Incredibly proud of our students and so excited for them to continue on their journey in medicine. And special thanks to my advisees for this amazing bobble head....:) Nailed it. #Match2023 #MedTwitter

Health 🤝🏽Technology 🤝🏽 Food. For the communities that need it most. Excited for this collaboration. Stanford Department of Medicine Instacart

The Will to Go On, by Sumit Shah, MD, MPH ascopost.com/issues/march-2… Sumit Shah Stanford Medicine

Current Issue: In Patients with Advanced Urothelial Carcinoma, Immune Checkpoint Inhibition Prior to Enfortumab Vedotin Is Associated with High-grade Skin Toxicity buff.ly/3KjH7nW Sandy Srinivas Sumit Shah Lisa Zaba MD PHD

Disheartening to see drug shortages for critical cancer therapies - cisplatin, carboplatin, and methotrexate among others. Oncologists are now having to triage and ration supply, which will inevitably affect outcomes. Can't help but notice that these are all generic drugs.

Truly historic. A new standard of care in advanced bladder cancer for the first time in 30 years. A doubling of overall survival from where we were a few yrs ago. Impressive ~30% complete response rate. Congrats to the investigators. Huge win for our patients. #ESMO23

So proud of our superstar Stanford Cancer Institute fellow, Mike Glover Mike Glover, on his work in bladder preservation strategies. Biomarkers hold promise to change the way we manage this cancer. What an exciting time to be an oncologist. #GU24 Jay B. Shah

Enjoyed chairing this panel on urologic cancers w/my partner in crime & superstar fellow, Mike Glover. Great discussion on everything from adjuvant immunotherapy to AI-derived biomarkers w/ a ⭐️ studded panel of experts Vadim Koshkin MD Felix Feng @mitsiades Geoffrey A. Sonn, MD SamWashUro

Just wrapped up my 20 yr reunion at Duke University - what an incredible weekend. It turns out that those peripheral relationships are so meaningful - they offer reflection on a very formative time, but also on what matters most: connection. Go to reunions. You won’t regret it.

Lots of exciting data at #ASCO24, but my favorite moment was this tribute by Christian Blank to his late mother, a late physician/scientist in the lab, & a late medical student. They all dedicated their lives to improving the lives of people with cancer. And they did. Beautiful.

Great collaborative effort here on the prognostic and possibly predictive value of #ctDNA in localized bladder cancer. Looking forward to the prospective data. Kudos to Mike Glover for leading the Stanford Cancer Institute effort.